Oruka Therapeutics, Inc. (ORKA) · Oct 26, 2026 · Other events

Oruka psoriasis earnings? Phase 2 data clears bar at 61%

Above the bar — PASI 100 61% vs 0% placebo; p<0.0001

Oruka’s Phase 2 psoriasis data validate ORKA-001 across two trials, supporting Phase 3 while annual dosing remains unproven.

Oruka is a clinical-stage biotech trying to turn ultra-long-acting antibodies into psoriasis treatments dosed once or twice a year; ORKA-001 is its lead IL-23p19 program, while ORKA-002 is the other major dermatology program.

The efficacy result clears the trial’s bar decisively. The Phase 2b EVERLAST-B study met its primary endpoint, with 61% of patients on the 600 mg dose reaching complete skin clearance at Week 16 versus 0% on placebo, with p<0.0001. 〔0〕 (Efficacy results — EVERLAST-B) The 86% PASI 90 rate and 86% IGA 0/1 rate reinforce that the result was not dependent on a single unusually strict endpoint. (Exhibit 99.1, Efficacy results)

MeasureORKA-001 600 mgPlaceboComparison
PASI 100 at Week 1661%0%Primary endpoint; p<0.0001 (Efficacy results — EVERLAST-B)
PASI 90 at Week 1686%Not stated in releaseSecondary endpoint (Efficacy results — EVERLAST-B)
IGA 0/1 at Week 1686%Not stated in releaseSecondary endpoint (Efficacy results — EVERLAST-B)
At least one TEAE39%43%Comparable overall event rate (Safety results — EVERLAST-B)
Serious TEAEs0%Not stated in releaseNone in the high-dose group (Safety results — EVERLAST-B)

The important upgrade is replication, not just another favorable percentage. EVERLAST-B was a larger, global Phase 2b trial with 187 patients and less than 30% site overlap with EVERLAST-A, yet the high-dose response was broadly consistent with the earlier study. 〔1〕 (Trial design — EVERLAST-B) That makes the program’s efficacy signal more credible and gives Oruka a basis to select 600 mg for Phase 3, although the company’s comparisons with approved IL-23 drugs remain cross-trial rather than head-to-head. (Presentation, slides 8, 11-12, 17)

Safety supports advancement but does not yet prove the commercial dosing promise. The high-dose group had fewer reported treatment-emergent adverse events than placebo, no serious TEAEs, and no injection-site reactions. 〔2〕 〔3〕 (Safety results — EVERLAST-B) However, the central value proposition—durable clearance with annual or semiannual dosing—still depends on longer-term maintenance data, not this Week 16 induction readout.

The filing advances Oruka from proof-of-concept toward execution. Management plans to discuss Phase 3 with regulators and start Phase 3 psoriasis trials in the first half of 2027 using the 600 mg dose, subject to those discussions. 〔4〕 (Development plans) The stated $1.1 billion cash position is intended to fund operations through an anticipated ORKA-001 BLA filing and continued ORKA-002 development, reducing the immediate need for financing to advance this program. (Cash Position)

Bottom line: EVERLAST-B materially strengthens the ORKA-001 story by independently reproducing a striking efficacy signal and selecting the Phase 3 dose. The remaining proof point is durability: whether the unusually strong Week 16 clearance persists with once-yearly or twice-yearly dosing.

What to watch next

52-week EVERLAST-A data, December 2026

Original filing on SEC EDGAR

More Oruka Therapeutics, Inc. news

Oruka psoriasis earnings? Phase 2 data clears bar at 61% | ORKA Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.